Cargando…

Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG(1) and IgG(4) against the Major Birch Pollen Allergen Bet v 1

Birch pollen allergy is among the most prevalent pollen allergies in Northern and Central Europe. This IgE-mediated disease can be treated with allergen immunotherapy (AIT), which typically gives rise to IgG antibodies inducing tolerance. Although the main mechanisms of allergen immunotherapy (AIT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Köhler, Verena K., Crescioli, Silvia, Fazekas-Singer, Judit, Bax, Heather J., Hofer, Gerhard, Pranger, Christina L., Hufnagl, Karin, Bianchini, Rodolfo, Flicker, Sabine, Keller, Walter, Karagiannis, Sophia N., Jensen-Jarolim, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460837/
https://www.ncbi.nlm.nih.gov/pubmed/32784509
http://dx.doi.org/10.3390/ijms21165693
_version_ 1783576688018325504
author Köhler, Verena K.
Crescioli, Silvia
Fazekas-Singer, Judit
Bax, Heather J.
Hofer, Gerhard
Pranger, Christina L.
Hufnagl, Karin
Bianchini, Rodolfo
Flicker, Sabine
Keller, Walter
Karagiannis, Sophia N.
Jensen-Jarolim, Erika
author_facet Köhler, Verena K.
Crescioli, Silvia
Fazekas-Singer, Judit
Bax, Heather J.
Hofer, Gerhard
Pranger, Christina L.
Hufnagl, Karin
Bianchini, Rodolfo
Flicker, Sabine
Keller, Walter
Karagiannis, Sophia N.
Jensen-Jarolim, Erika
author_sort Köhler, Verena K.
collection PubMed
description Birch pollen allergy is among the most prevalent pollen allergies in Northern and Central Europe. This IgE-mediated disease can be treated with allergen immunotherapy (AIT), which typically gives rise to IgG antibodies inducing tolerance. Although the main mechanisms of allergen immunotherapy (AIT) are known, questions regarding possible Fc-mediated effects of IgG antibodies remain unanswered. This can mainly be attributed to the unavailability of appropriate tools, i.e., well-characterised recombinant antibodies (rAbs). We hereby aimed at providing human rAbs of several classes for mechanistic studies and as possible candidates for passive immunotherapy. We engineered IgE, IgG(1), and IgG(4) sharing the same variable region against the major birch pollen allergen Bet v 1 using Polymerase Incomplete Primer Extension (PIPE) cloning. We tested IgE functionality and IgG blocking capabilities using appropriate model cell lines. In vitro studies showed IgE engagement with FcεRI and CD23 and Bet v 1-dependent degranulation. Overall, we hereby present fully functional, human IgE, IgG(1), and IgG(4) sharing the same variable region against Bet v 1 and showcase possible applications in first mechanistic studies. Furthermore, our IgG antibodies might be useful candidates for passive immunotherapy of birch pollen allergy.
format Online
Article
Text
id pubmed-7460837
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74608372020-09-03 Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG(1) and IgG(4) against the Major Birch Pollen Allergen Bet v 1 Köhler, Verena K. Crescioli, Silvia Fazekas-Singer, Judit Bax, Heather J. Hofer, Gerhard Pranger, Christina L. Hufnagl, Karin Bianchini, Rodolfo Flicker, Sabine Keller, Walter Karagiannis, Sophia N. Jensen-Jarolim, Erika Int J Mol Sci Article Birch pollen allergy is among the most prevalent pollen allergies in Northern and Central Europe. This IgE-mediated disease can be treated with allergen immunotherapy (AIT), which typically gives rise to IgG antibodies inducing tolerance. Although the main mechanisms of allergen immunotherapy (AIT) are known, questions regarding possible Fc-mediated effects of IgG antibodies remain unanswered. This can mainly be attributed to the unavailability of appropriate tools, i.e., well-characterised recombinant antibodies (rAbs). We hereby aimed at providing human rAbs of several classes for mechanistic studies and as possible candidates for passive immunotherapy. We engineered IgE, IgG(1), and IgG(4) sharing the same variable region against the major birch pollen allergen Bet v 1 using Polymerase Incomplete Primer Extension (PIPE) cloning. We tested IgE functionality and IgG blocking capabilities using appropriate model cell lines. In vitro studies showed IgE engagement with FcεRI and CD23 and Bet v 1-dependent degranulation. Overall, we hereby present fully functional, human IgE, IgG(1), and IgG(4) sharing the same variable region against Bet v 1 and showcase possible applications in first mechanistic studies. Furthermore, our IgG antibodies might be useful candidates for passive immunotherapy of birch pollen allergy. MDPI 2020-08-08 /pmc/articles/PMC7460837/ /pubmed/32784509 http://dx.doi.org/10.3390/ijms21165693 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Köhler, Verena K.
Crescioli, Silvia
Fazekas-Singer, Judit
Bax, Heather J.
Hofer, Gerhard
Pranger, Christina L.
Hufnagl, Karin
Bianchini, Rodolfo
Flicker, Sabine
Keller, Walter
Karagiannis, Sophia N.
Jensen-Jarolim, Erika
Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG(1) and IgG(4) against the Major Birch Pollen Allergen Bet v 1
title Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG(1) and IgG(4) against the Major Birch Pollen Allergen Bet v 1
title_full Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG(1) and IgG(4) against the Major Birch Pollen Allergen Bet v 1
title_fullStr Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG(1) and IgG(4) against the Major Birch Pollen Allergen Bet v 1
title_full_unstemmed Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG(1) and IgG(4) against the Major Birch Pollen Allergen Bet v 1
title_short Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG(1) and IgG(4) against the Major Birch Pollen Allergen Bet v 1
title_sort filling the antibody pipeline in allergy: pipe cloning of ige, igg(1) and igg(4) against the major birch pollen allergen bet v 1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460837/
https://www.ncbi.nlm.nih.gov/pubmed/32784509
http://dx.doi.org/10.3390/ijms21165693
work_keys_str_mv AT kohlerverenak fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT cresciolisilvia fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT fazekassingerjudit fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT baxheatherj fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT hofergerhard fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT prangerchristinal fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT hufnaglkarin fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT bianchinirodolfo fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT flickersabine fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT kellerwalter fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT karagiannissophian fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1
AT jensenjarolimerika fillingtheantibodypipelineinallergypipecloningofigeigg1andigg4againstthemajorbirchpollenallergenbetv1